The telehealth company Hims & Hers has made waves for its Super Bowl ad that plugged its lower-priced form of injectable ...

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...

Q4 2024 Earnings Call Transcript February 24, 2025 Hims & Hers Health, Inc. beats earnings expectations. Reported EPS is $0.11, expectations were $0.09. Operator: Good afternoon, ladies and gentlemen, ...

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...

A series of important developments in the healthcare sector includes Medtronic adapting to tariff threats, Hims & Hers facing ...

Shares of Hims & Hers Health tumbled 18% premarket on Tuesday as Wall Street analysts questioned the telehealth provider's ...

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...

Ahead of whatever Jensen Huang & Co. announces, let's look at another highflying stock: Costco Wholesale (COST). Christopher Bloomstran, the president and chief investment officer St. Louis-based ...

Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...

Schumacher is stepping down by mutual agreement on Saturday, before leaving the company on May 31. Japanese trading-house stocks rose sharply after Warren Buffett said Berkshire Hathaway's stakes in ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

UnitedHealth Group, Alphabet, Hims & Hers Health, Salesforce, and Johnson & Johnson are the five Healthcare stocks to watch today, according to MarketBeat’s stock screener tool. These companies had ...